Patrick Flynn

Healthcare Executive

📍 Concord, Massachusetts, United States🔄 Updated September 2026💼 4 investments📅 13 years investing🗓 Last invested Dec 2017
Angel investor🌍 United States
4
Total investments
2
Early stage
0
Mid stage
0
Late stage
13y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Dec 2017
NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience to address very high unmet needs of patients and bring improved health to patients. The U.S. Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
Board Member
Jun 2013
Common Sensing is building the next generation of accessible smart health technology for people who use disposable pen-injectors. Based in Cambridge, MA, our team has a progressive and authentic culture where strong teamwork builds the foundation of everything we do. Our Gocap® System utilizes a smart cap for disposable pen-injectors that automatically sends drug-delivery data to a connected phone app.
Experience · 5 entries
All (5)
Investments (4)
Board (4)
2017
NeuroRx, Inc.
Board Member
Dec 2017
Board Member
Dec 2017
NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience to address very high unmet needs of patients and bring improved health to patients. The U.S. Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
2014
Brown Brothers Harriman's Healthcare Advisory Board
Board Member
Oct 2014
2013
Board Member
Jun 2013
Common Sensing is building the next generation of accessible smart health technology for people who use disposable pen-injectors. Based in Cambridge, MA, our team has a progressive and authentic culture where strong teamwork builds the foundation of everything we do. Our Gocap® System utilizes a smart cap for disposable pen-injectors that automatically sends drug-delivery data to a connected phone app.
2010
Assabet Ventures
Partner
Mar 2010
Investment activity
2013–2017 · 4 investments
201312014120172
Recent (last 2 years)Earlier